drug_type
RELEVANT_DRUG
intervention_type
Biologic drug (anti-TNF monoclonal antibody)
drug_description
Chimeric IgG1 monoclonal antibody targeting soluble and transmembrane TNF-α; blocks TNFR1/2-mediated signaling to reduce NF-κB–driven inflammation (cytokines/chemokines, adhesion molecules, leukocyte trafficking) and can induce apoptosis of activated TNF-expressing immune cells.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-alpha, neutralizing TNF and preventing TNFR1/2 signaling. This suppresses NF-kB–driven inflammatory pathways (proinflammatory cytokines/chemokines, adhesion molecules, leukocyte trafficking) and can induce apoptosis of activated TNF-expressing immune cells via Fc-mediated effects/reverse signaling.
drug_name
Infliximab
nct_id_drug_ref
NCT05781152